Apremilast for treatment of recurrent erythema multiform

Tinley Chen, Jacob Levitt, Lauren Geller

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Recurrent erythema multiforme with oral involvement is therapeutically challenging. Apremilast has been used with success in resolving the oral aphthae of Behcet disease, prompting the use of the drug in patients with oral erosions from erythema multiforme. Three patients with oral erythema multiforme were given apremilast at doses of 30-60mg daily. Complete clearance of the lesions were observed in all three patients, including those refractory to other standard therapies. Apremilast may present an effective option for recurrent erythema multiforme for patients who have failed trials antiviral and immunosuppressive therapies.

Original languageEnglish
Article number14
JournalDermatology Online Journal
Issue number1
StatePublished - 2016


  • Apremilast
  • Behçet’s syndrome
  • EM
  • Erythema multiforme
  • Otezla
  • REM
  • Recurrent erythema multiforme


Dive into the research topics of 'Apremilast for treatment of recurrent erythema multiform'. Together they form a unique fingerprint.

Cite this